Generic Name and Formulations:
Synthetic conjugated estrogens, B, 0.3mg, 0.45mg, 0.625mg, 0.9mg, 1.25mg; tabs.
Indications for ENJUVIA:
Moderate-to-severe vasomotor symptoms of menopause. Moderate-to-severe vaginal dryness and pain with intercourse, symptoms of vulvar and vaginal atrophy, due to menopause.
Use lowest effective dose for shortest duration. Initially 0.3mg once daily. Reevaluate periodically.
Undiagnosed abnormal uterine bleeding. Known, suspected or history of breast cancer. Known or suspected estrogen-dependent neoplasia. Active DVT, PE or history of. Active arterial thromboembolic disease or history of. Hepatic impairment. Known protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders. Pregnancy.
Not for prevention of cardiovascular disease or dementia. Increased risk of cardiovascular disorders (eg, stroke, DVT, VTE); discontinue if occurs or suspected. Manage risk factors for CVD and VTE appropriately. Increased risk of endometrial carcinoma or hyperplasia in women with intact uterus (adding progestin is essential). Risk of probable dementia in women ≥65yrs of age. Discontinue at least 4–6 weeks before surgery type associated with increased risk of thromboembolism or during prolonged immobilization. Breast or ovarian cancer. Gallbladder disease. Bone disease associated hypercalcemia. Visual abnormalities. Hypertriglyceridemia. Discontinue if cholestatic jaundice, pancreatitis, loss of vision, or hypercalcemia occurs. Hypothyroidism. Conditions aggravated by fluid retention (eg, cardiac or renal impairment). Hypoparathyroidism. Hereditary angioedema. Asthma. Diabetes. Epilepsy. Migraine. Porphyria. SLE. Hepatic hemangiomas. Do initial complete physical (include BP, mammogram, PAP smear) and repeat annually. Nursing mothers.
May be antagonized by CYP3A4 inducers (eg, phenobarbital, carbamazepine, rifampin, St. John’s wort). May be potentiated by CYP3A4 inhibitors (eg, erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir, grapefruit juice). May interfere with lab tests (eg, PT, thyroid, glucose tolerance, HDL/LDL, triglycerides, hormone concentrations, other binding proteins).
Abdominal pain, headache, pain, nausea, mastodynia, irregular bleeding, vaginitis, dysmenorrhea, paresthesia, breast tenderness, back pain, edema, hypertension, visual abnormalities, hypertriglyceridemia, dementia.
- Neurotoxicity After CAR T-cell Therapy May Be Associated With Endothelial Activation
- Navigation Programs Most Effective in Increasing Follow-up Colonoscopy
- New Class of Clinical Trial Enhances Research on Cancer Care Delivery
- Nivolumab Provides Better Long-Term Efficacy Compared With Docetaxel in NSCLC
- Prophylactic Prochloperazine Ineffective for Opioid-induced Nausea/Vomiting in Cancer
- Anticancer Properties of The Probiotic Kefir: A Review
- Combining Radiation, Immunotherapy: An Emerging Challenge for Oncology Nursing
- Navigating the Transition From Treatment to Breast Cancer Survivor
- Naldemedine Effective for Opioid-Induced Constipation in Cancer Pain
- Disruptions to Circadian Rhythm Linked to Prostate Cancer Surgery Regret
- A Case of Immunotherapy-Induced Myocarditis Concomitant to MG in Lung Cancer
- Daily Aspirin Reduced Risk of HBV-Related Hepatocellular Carcinoma
- Lanreotide Effectively Controls Diarrhea, Flushing in Neuroendocrine Tumors
- Case Report of a KIT-mutated Melanoma Patient With an Excellent Response to Apatinib and Temozolomide Combination Therapy
- Novel Predictive Model More Effectively Identifies Risk for Lung Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|